Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Theriva Biologics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +4 vs. Q1 2026
- Shares held
- 1.98M
- +15.1K (+0.8%) vs. Q1 2026
- Total value
- $495.5K
- +$110.2K (+28.6%) vs. Q1 2026
- New holders
- 6
- 5 more added
- Sold out
- 2
- 6 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TOVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $495.5K |
| Q1 2026 | 22 | $385.4K |
| Q4 2025 | 21 | $272.4K |
| Q3 2025 | 20 | $177.0K |
| Q2 2025 | 17 | $126.3K |
| Q1 2025 | 11 | $209.8K |
| Q4 2024 | 10 | $60.3K |
| Q3 2024 | 18 | $678.6K |
| Q2 2024 | 22 | $327.6K |
| Q1 2024 | 24 | $366.3K |
| Q4 2023 | 24 | $452.3K |
| Q3 2023 | 21 | $572.8K |
| Q2 2023 | 18 | $1.01M |
| Q1 2023 | 19 | $724.6K |
| Q4 2022 | 22 | $477.1K |
| Q3 2022 | 26 | $1.15M |
| Q2 2022 | 33 | $2.51M |
| Q1 2022 | 35 | $3.17M |
| Q4 2021 | 35 | $3.24M |
| Q3 2021 | 36 | $3.32M |
| Q2 2021 | 31 | $3.91M |
| Q1 2021 | 32 | $5.80M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Theriva Biologics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Danske Bank A/S | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 5 | $1 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 3 | $1 | 0.00% | +3 | New |
| IFP Advisors, Inc | 11 | $3 | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 100 | $25 | 0.00% | +100 | New |
| SBI Securities Co., Ltd. | 358 | $90 | 0.00% | +227+173.3% | Added |
| Advisor Group Holdings, Inc. | 441 | $110 | 0.00% | +433+5,412.5% | Added |
| BlackRock, Inc. | 7,504 | $1.88K | 0.00% | 00.0% | Unchanged |
| Schwarz Dygos Wheeler Investment Advisors LLC | 15,000 | $3.75K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 15,456 | $3.87K | 0.00% | +15+0.1% | Added |
| Two Sigma Securities, LLC | 19,748 | $4.94K | 0.00% | −85,493−81.2% | Reduced |
| Morgan Stanley | 20,299 | $5.08K | 0.00% | −3,303−14.0% | Reduced |
| Susquehanna International Group, LLP | 24,064 | $6.02K | 0.00% | +24,064 | New |
| Boothbay Fund Management, LLC | 27,646 | $6.92K | 0.00% | 00.0% | Unchanged |
| Ground Swell Capital, LLC | 35,292 | $8.83K | 0.01% | +35,292 | New |
| XTX Topco Ltd | 53,868 | $13.5K | 0.00% | −40,752−43.1% | Reduced |
| UBS Group AG | 61,053 | $15.3K | 0.00% | −164,571−72.9% | Reduced |
| Renaissance Technologies LLC | 63,710 | $15.9K | 0.00% | +63,710 | New |
| Northern Trust Corp | 82,700 | $20.7K | 0.00% | +82,700 | New |
| Virtu Financial LLC | 87,138 | $22.0K | 0.00% | −166,080−65.6% | Reduced |
| Ikarian Capital, LLC | 112,076 | $28.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 241,780 | $60.4K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 294,021 | $73.6K | 0.00% | −156,242−34.7% | Reduced |
| Jane Street Group, LLC | 331,922 | $83.0K | 0.00% | +154,888+87.5% | Added |
| Vanguard Capital Management LLC | 486,179 | $121.5K | 0.00% | +293,775+152.7% | Added |
| StoneX Group Inc. | 0 | $0 | 0.00% | −22,280−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1,391−100.0% | Sold out |